Vetter ramps up lyophilisation capacity at German plant
The expansion, which is a gives the contract manufacturing organisation (CMO) 30 per cent more lyophilisation capacity, means the site can now produce up to 24m units annually.
Vetter said it made the investment to meet future demand for aseptically filled biologics and other sensitive compounds, citing the fact that just under a third of all drugs approved in the US in the last three years were biologics.
Peter Soelkner, Managing Director at Vetter said: "They [biologics] have become pivotal components of the portfolio and strategy of many pharmaceutical and biotech companies, which are continuously developing new drugs in this segment.
“In turn, as a strategic partner to our clients, we continuously invest in the infrastructure and equipment needed to support their needs in commercial manufacturing."
